Duality Biologics Signs Exclusive Option Agreement with GSK for ADC Candidate DB-1324 in Gastrointestinal Cancer

 Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...

December 04, 2024 | Wednesday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Kelun-Biotech's Sacituzumab Tirumotecan (Sac-TMT) Gains Marketing Approval for Advanced TNBC in China

The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...

December 02, 2024 | Monday | News
Ascentage Pharma’s Olverembatinib Gains Expanded Inclusion in China’s 2024 National Reimbursement Drug List

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...

November 29, 2024 | Friday | News
West China Lecheng Hospital Launches Vorasidenib, First-in-Class Targeted Therapy for IDH-Mutant Glioma

It was announced that West China Lecheng Hospital has successfully introduced Vorasidenib for treatment at clinical practices, and the treatment began at o...

November 25, 2024 | Monday | News
AstraZeneca’s Tagrisso (osimertinib) Recommended for EU Approval in Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...

November 19, 2024 | Tuesday | News
GSK’s Blenrep Combination Demonstrates Significant Survival Benefit in Relapsed/Refractory Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...

November 15, 2024 | Friday | News
IDEAYA Secures Global Rights to Biocytogen’s Innovative BsADC Candidate, IDE034

IDEAYA Secures Exclusive Global License for Biocytogen’s First-In-Class BsADC, B7H3/PTK7 Topo-I Payload (IDE034), Validating Biocytogen’s Ren...

November 12, 2024 | Tuesday | News
Zai Lab and argenx Secure Historic NMPA Approval for First CIDP Treatment in China

First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab&rs...

November 12, 2024 | Tuesday | News
Abbisko's Phase 3 Study of Pimicotinib Shows Statistically Significant Efficacy in Treating Tenosynovial Giant Cell Tumor (TGCT)

Abbisko announced that the Phase 3 MANEUVER study evaluating pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) achieved statistically si...

November 12, 2024 | Tuesday | News
IASO Biotherapeutics’ Anti-BCMA CAR-T Therapy Fucaso™ Shows Strong Efficacy in Treating Relapsed/Refractory Multiple Myeloma in Phase 1b/2 Study Published in JAMA Oncology

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ther...

November 08, 2024 | Friday | News
Duoning Biotechnology and Branca Bunús Form Strategic Alliance to Enhance Transfection Reagents for Biopharma Innovation

Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agree...

November 06, 2024 | Wednesday | News
BioCity Biopharma Unveils Positive Late-Breaking Results from 2-SUCCEED Trial of SC0062 for IgA Nephropathy at ASN Kidney Week 2024

BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...

November 05, 2024 | Tuesday | News
GSK Acquires CMG1A46 from Chimagen for $300 Million to Target B Cell-Driven Autoimmune Diseases

GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a c...

October 30, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close